Ugrás a tartalomra
Merck
Összes fotó(1)

Fontos dokumentumok

View All Documentation

B7431

Sigma-Aldrich

Bryostatin 1

≥99%, solid

Szinonimák:

NSC 339555

Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez
Összes fotó(1)

About This Item

Tapasztalati képlet (Hill-képlet):
C47H68O17
CAS-szám:
83314-01-6
Molekulatömeg:
905.03
MDL-szám:
MFCD00893832
UNSPSC kód:
12352200
PubChem Substance ID:
24891991
NACRES:
NA.77

Minőségi szint

100

Teszt

≥99%

form

solid

szín

white

oldhatóság

DMSO: soluble
ethanol: soluble

tárolási hőmérséklet

−20°C

SMILES string

[H]\C(C(=O)OC)=C1/C[C@@]2([H])C[C@]3(O)O[C@]([H])(C[C@@H](O)CC(=O)O[C@H](C[C@]4([H])C\C(=C(\[H])C(=O)OC)[C@H](OC(=O)\C=C\C=C\CCC)[C@@](O)(O4)C(C)(C)\C=C\[C@@]([H])(C1)O2)[C@@H](C)O)C[C@H](OC(C)=O)C3(C)C

InChI

1S/C47H68O17/c1-10-11-12-13-14-15-39(51)62-43-31(22-41(53)58-9)21-34-25-37(28(2)48)61-42(54)24-32(50)23-35-26-38(59-29(3)49)45(6,7)46(55,63-35)27-36-19-30(20-40(52)57-8)18-33(60-36)16-17-44(4,5)47(43,56)64-34/h12-17,20,22,28,32-38,43,48,50,55-56H,10-11,18-19,21,23-27H2,1-9H3/b13-12+,15-14+,17-16+,30-20+,31-22+/t28-,32-,33+,34+,35-,36+,37-,38+,43+,46+,47-/m1/s1

Nemzetközi kémiai azonosító kulcs

MJQUEDHRCUIRLF-TVIXENOKSA-N

Alkalmazás

Bryostatin 1 has been used to study its effects on spontaneous Crohn′s disease (CD) like colitis in mice. It has also been used to study its effects as an anthelmintic drug on adult Syphacia muris infection in rats.

Biokémiai/fiziológiai hatások

Bryostatin 1 (Bry1) is a macrocyclic lactone. This synaptogenic compound is obtained from the marine bryozoan Bugula neritina. Bry1 is capable of reversing synaptic loss. It can enable synaptic maturation in animal models with several neurological disorders. It possesses antidepressant activity, when administered intracebroventricularly. Bry1 is known to participate in protecting cell tight junctions (TJs), anti-inflammatory functions and immune regulation.
Macrolactone isolated from the marine bryozoan Bugula neritina that initially activates and subsequently down-regulates protein kinase C (PKC). More potent than phorbol myristate acetate for translocating PKCδ and ε.

Egyéb megjegyzések

Binds to glass and plastic in aqueous solutions

Tárolási osztály kódja

11 - Combustible Solids

WGK

WGK 3

Lobbanási pont (F)

Not applicable

Lobbanási pont (C)

Not applicable

Egyéni védőeszköz

Eyeshields, Gloves, type N95 (US)

Analitikai tanúsítványok (COA)

Analitikai tanúsítványok (COA) keresése a termék sarzs-/tételszámának megadásával. A sarzs- és tételszámok a termék címkéjén találhatók, a „Lot” vagy „Batch” szavak után.

Már rendelkezik ezzel a termékkel?

Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.

Dokumentumtár megtekintése

Jarin Hongpaisan et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 31(2), 630-643 (2011-01-14)
Among the pathologic hallmarks of Alzheimer's disease (AD) neurodegeneration, only synaptic loss in the brains of AD patients closely correlates with the degree of dementia in vivo. Here, we describe a molecular basis for this AD loss of synapses: pathological
B Douglas Smith et al.
Leukemia research, 35(1), 87-94 (2010-07-06)
Pharmacologic differentiating agents have had relatively limited clinical success outside of the use of ATRA in acute promyelocytic leukemia and DNA methyltransferase inhibitors in myelodysplastic syndromes. The differentiating effects of such agents can be enhanced in combination with lineage-specific growth
Maria Eugenia Ariza et al.
The Journal of biological chemistry, 286(1), 24-34 (2010-11-03)
Bryostatin-1 (Bryo-1), a natural macrocyclic lactone, is clinically used as an anti-cancer agent. In this study, we demonstrate for the first time that Bryo-1 acts as a Toll-like receptor 4 (TLR4) ligand. Interestingly, activation of bone marrow-derived dendritic cells (in
Maciej Kmieciak et al.
Journal of visualized experiments : JoVE, (47)(47), doi:10-doi:10 (2011-02-10)
It was reported that breast cancer patients have pre-existing immune responses against their tumors(1,2). However, such immune responses fail to provide complete protection against the development or recurrence of breast cancer. To overcome this problem by increasing the frequency of
Moisés Pérez et al.
Current HIV research, 8(6), 418-429 (2010-07-20)
The persistence of latent HIV-infected cellular reservoirs represents the major hurdle to virus eradication on patients treated with HAART. It has been suggested that successful depletion of such latent reservoirs will require a combination of therapeutic agents that can specifically
View All Related Papers

Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.

Lépjen kapcsolatba a szaktanácsadással